Pfizer Inc. (PFE), on Thursday, announced positive results from the Phase 3 PATINA trial, evaluating the addition of IBRANCE for treating metastatic breast cancer.
The trial, sponsored by Alliance Foundation Trials (AFT), LLC, evaluates the efficacy and safety of IBRANCE, an oral inhibitor, with anti-HER2 therapy and endocrine therapy in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer.
About 10% of all breast cancers are HR-positive and HER2-positive, often referred to as double-positive or triple-positive breast cancer.
In the study, the median progression-free survival (PFS) was 44.3 months for patients treated with IBRANCE in combination with anti-HER2 therapy and endocrine therapy, and 29.1 months for patients treated with anti-HER2 therapy and endocrine therapy alone.
IBRANCE, approved in 2015, is used for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
PFE closed Wednesday's trading at $25.23, down by 1.33 percent on the New York Stock Exchange.
For comments and feedback: editorial@rttnews.com